Cargando…
PD‐L1‐negative non‐small cell lung cancer harbouring a rare BRAF mutation with successful treatment of first‐line pembrolizumab plus chemotherapy: A case report and review the literature
BRAF mutations are uncommon in non‐small cell lung cancer (NSCLC), accounting for less than 5% of all NSCLC cases. The utilization of targeted therapies in non‐V600E BRAF mutant NSCLC is considered controversial, although non‐V600E genotype is reported in ~50% of all BRAF mutant patients. We documen...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Ltd
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156919/ https://www.ncbi.nlm.nih.gov/pubmed/37151366 http://dx.doi.org/10.1002/rcr2.1155 |